San Diego, California — September 4, 2026
Modular Medical announced that it has secured a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to the company’s Pivot™ tubeless patch pump through the PBM’s network. The agreement represents an important commercialization milestone for Modular Medical as it prepares for the broader launch of its next-generation insulin delivery system. Under the contract, the Pivot insulin delivery system is now available through the national PBM, creating an additional pathway for eligible patients to access the technology through existing healthcare benefits. Modular Medical believes the agreement can broaden the reach of Pivot among people living with diabetes who require intensive insulin therapy and further support the company’s strategy of developing a simpler and more accessible alternative to conventional insulin pump systems. The PBM contract follows recent commercialization activities as Modular Medical moves Pivot toward wider U.S. market availability.
Modular Medical Strengthens Pivot Commercialization Strategy
The PBM agreement gives Modular Medical an important channel for expanding the commercial footprint of Pivot as the company prepares to introduce the device across selected U.S. markets. Pharmacy benefit managers play an important role in the U.S. healthcare system by working with health plans, employers, pharmacies, and manufacturers to manage prescription benefits, reimbursement arrangements, and formulary access. For medical technologies such as insulin delivery systems, establishing relationships with benefit managers can help reduce barriers that may otherwise limit patient access. Modular Medical said the agreement with the unnamed national PBM, which the company described as one of the largest in the country, positions Pivot to reach more patients who could benefit from a wearable, tubeless insulin delivery system. The financial terms and identity of the PBM were not disclosed.
Pivot Designed for Simplified Insulin Delivery
The Pivot™ tubeless patch pump is a wearable insulin delivery platform designed to provide continuous subcutaneous insulin infusion, including both basal and bolus insulin delivery, over a three-day wear period. Modular Medical has positioned the system as a practical pathway for people currently using multiple daily injections who may be considering insulin pump therapy. The company’s approach focuses on simplifying insulin delivery while maintaining the functionality required for intensive insulin therapy. By eliminating traditional external tubing and incorporating the insulin delivery mechanism into a wearable patch format, Pivot is intended to provide a more approachable user experience for a broader diabetes population. Modular Medical has described its goal as making insulin pump therapy more accessible by reducing complexity and improving ease of use. The company has also been preparing for its planned commercial rollout, with recent company updates indicating an initial commercialization phase across five U.S. markets beginning in October 2026
Advertisement
Modular Medical Advances Patient Access Ahead of Launch
The national PBM agreement adds another component to Modular Medical’s broader commercialization strategy for Pivot. Earlier preparations have included real-world patient onboarding and training, clinical and commercial initiatives, and efforts to establish healthcare-system pathways that can support adoption of the tubeless insulin pump. The company has also received FDA clearance for software enhancements to Pivot, including expanded bolus-dosing functionality and user-interface improvements ahead of the planned commercial launch. Jeb Besser, Chief Executive Officer of Modular Medical, described the national PBM agreement as an important commercialization milestone, emphasizing the role of PBMs in enabling patient access to medical technologies. For Modular Medical, securing national benefit-manager access represents a step toward translating Pivot’s device technology into broader patient availability. As the company progresses toward its U.S. commercial launch, the PBM relationship could help establish a more structured reimbursement and access pathway for people seeking alternatives to multiple daily insulin injections.
Source: Modular Medical, press relese
